Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Snow (NPI 1639177082)

Field	Value
Entity Type	Individual
Organization	David Snow
Address	27056 Andrew Jackson Hwy E
City	Delco
State	NC
ZIP	28436
Taxonomy	Rheumatology Physician
NPI Enumerated	July 11, 2005

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

Lifetime Medicare revenue for this Rheumatology Physician is $3.4M and there is no Medicaid billing on file, making the provider effectively single-payer (Medicare) in scale. The absence of Medicaid activity indicates limited state-program participation or a referral/payer mix concentrated on Medicare and commercial payers rather than Medicaid patients.

Revenue is highly concentrated in a small set of biologic/infusion drugs: the top three Medicare codes (J0129, J3262, J1602) account for 56.0% of this provider's total Medicare revenue. Those top codes individually contribute $941.3K (J0129, 27.6%), $532.8K (J3262, 15.6%), and $435.6K (J1602, 12.8%), signaling heavy reliance on high-cost injectable therapies.

The code mix (J0129 abatacept, J3262 tocilizumab, J1602 golimumab and others such as J3111 romosozumab and J0717 certolizumab pegol) indicates the practice operates as an infusion/biologics center treating inflammatory and bone-density conditions typical of rheumatology. Presence of multiple high-revenue biologic injection codes suggests the business model is centered on drug administration rather than generating the majority of revenue from evaluation-and-management office visits.

Competitive standing varies by code: the provider ranks #55 of 1221 for J0129 at the 96th percentile and is described as notably above typical national volume for that code, indicating a major national presence for abatacept administration. Other high-revenue biologic codes (J3262 rank #44 of 618, 93th percentile; J1602 rank #85 of 1041, 92th percentile) are in high national percentiles but are labeled as typical or unremarkable volume for those codes, suggesting above-average scale without being uniquely dominant across every biologic.

The practice reports unusually high activity in infusion/administration CPTs for systemic therapies: 96413 (chemotherapy infusion) and 96401 (subcutaneous/intramuscular chemotherapy administration) are both flagged as extreme outliers at the 99th percentile. Those extreme outlier labels, together with non-oncology biologic infusions in the top revenue mix, point to a substantial infusion suite or high throughput infusion operations that exceed typical rheumatology peers.

Beyond the top biologics, additional codes contributing meaningful Medicare revenue include J3111 ($433.4K, 12.7%) and J0717 ($382.4K, 11.2%), reflecting a diversified biologic portfolio that spans osteoporosis and multiple anti-inflammatory biologic agents. These mid-to-high revenue biologic codes further reinforce that drug administration is the dominant service line driving income.

Evaluation-and-management codes generate comparatively modest revenue: 99214 ($42.4K, 1.2%) and 99215 ($20.4K, 0.6%) together represent a small slice of total Medicare revenue, indicating the practice’s economics are weighted toward procedural/drug reimbursement rather than office visit volume. This mix implies staffing, space, and operations are likely optimized for infusion delivery and medication handling rather than high-volume clinic visits.

The provider’s NPI was enumerated on 2005-07-11 (~21 years ago), indicating a long-tenured practice. Coupled with $3.4M in lifetime Medicare revenue and high national ranks on multiple biologic and infusion codes, this tenure supports the interpretation of an established, infusion-focused rheumatology operation with concentrated Medicare-dependent revenue exposure.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

34 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	28,530	$30	$941.3K
J3262	Injection, tocilizumab, 1 mg	106,550	$10	$532.8K
J1602	Injection, golimumab, 1 mg, for intravenous use	39,600	$10	$435.6K
J3111	Injection, romosozumab-aqqg, 1 mg	54,180	$10	$433.4K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	95,600	$1	$382.4K
J0897	Injection, denosumab, 1 mg	11,040	$20	$198.7K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4,940	$30	$128.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,020	$100	$99.6K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	2,720	$30	$87K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,160	$60	$63.7K

Showing 1–10 of 34

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

David Snow — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

34 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	4	70	9,530	$30	$393.2K
J3262	5	40	37,160	$1	$224.8K
J0717	4	40	37,400	$1	$178.8K
J1602	4	70	11,900	$10	$175.9K
J3111	1	30	13,970	$10	$135.8K
J1745	32	80	4,110	$30	$117.3K
Q5104	6	10	2,860	$30	$101.3K
J0897	20	430	2,100	$20	$63.9K
96413	2	280	90	$90	$15.8K
99214	1,535	18,060	110	$80	$15.1K

Showing 1–10 of 34

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Snow, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kirsten Siwy	NC	Medical Physician Assistant	$459.8K	$0
Erika Lynch	NC	Medical Physician Assistant	$69.7K	$0

Nearby Providers

Other providers in the same ZIP code as David Snow, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Richard Bumgardner	NC	Internal Medicine Physician	$135.9K	$0

David Snow — Billing Profile & Reimbursement Data

Sign up for David Snow — Billing Profile & Reimbursement Data policy alerts

David Snow — Billing Profile & Reimbursement Data

Sign up for David Snow — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References